Breaking News Instant updates and real-time market news.

TWX

Time Warner

$88.72

0.71 (0.81%)

, GE

General Electric

$18.21

-0.04 (-0.22%)

20:02
11/19/17
11/19
20:02
11/19/17
20:02

On The Fly: Top five weekend stock stories

Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Honda Motor (HMC) is recalling 900,000 minivans because second-row seats may tip forward if not properly latched after being adjusted, according to Reuters. 2. Galapagos NV (GLPG) reported positive topline results from its ALBATROSS Phase 2 study in cystic fibrosis patients with C1 corrector GLPG2222. The ALBATROSS study included 37 cystic fibrosis patients with a gating mutation on one allele and F508del mutation on the other allele. Primary objectives of this randomized, double-blinded, placebo controlled study were to evaluate the safety and tolerability and pharmacokinetics of novel C1 corrector GLPG2222 in this CF patient population. 3. Investors are warming to moderately priced blue chips, and IBM (IBM) could be the next "slumbering giant" that could fetch a higher valuation, Jack Hough wrote in this week's edition of Barron's. IBM's gross profit could grow in the current quarter for the first time in years, suggesting its big investment in analytic and cloud products are winning over customers, he noted, adding that a stock rebound could follow. 4. Warner Bros.' (TWX) "Justice League" opened to a disappointing $96M in North America, the lowest domestic opening of any title in the DC Extended Universe. Faring better overseas, the superhero mashup debuted to $185.5M from 65 markets. "Justice League" received a B+ CinemaScore and 37% from Rotten Tomatoes. 5. IBM (IBM) and Baker Hughes (BHGE) saw positive mentions in Barron's, while General Electric (GE) was mentioned cautiously.

TWX

Time Warner

$88.72

0.71 (0.81%)

GE

General Electric

$18.21

-0.04 (-0.22%)

IBM

IBM

$148.97

-0.15 (-0.10%)

BHGE

Baker Hughes

$30.91

0.76 (2.52%)

HMC

Honda

$32.62

0.02 (0.06%)

GLPG

Galapagos NV

$90.83

-0.66 (-0.72%)

  • 27

    Nov

  • 14

    Dec

TWX Time Warner
$88.72

0.71 (0.81%)

11/17/17
WELS
11/17/17
NO CHANGE
WELS
Wells sees 'exceedingly low' probability of Comcast, Fox deal
Following reports that Comcast (CMCSA) is looking to buy all or part of 21st Century Fox (FOXA), Wells Fargo analyst Marci Ryvicker says the likelihood of any deal being consummated is "exceedingly low." Amid the regulatory scrutiny over AT&T's (T) proposed vertical acquisition of Time Warner (TWX), Comcast would have an "exceptionally difficult time" completing a Fox merger as it would be both vertical and horizontal in nature, Ryvicker tells investors in a research note. The analyst points out, however, that her sum-of-the-parts analysis suggests Fox is worth $41 per share.
11/17/17
LOOP
11/17/17
NO CHANGE
Target $103
LOOP
Hold
Time Warner opens its 'most important film of the year', says Loop Capital
Loop Capital analyst David Miller says Time Warner's "Justice League", opening today, may be the studio's "most important film release of the year". Miller says that based on his sources and factoring in the success of "Wonder Woman", he anticipates $120M domestic opening box office total and leading up to $700M global cumulative take. The analyst also notes that the "central issue at hand" for the company being the latest snag from Department of Justice chief antitrust officer Makan Delrahim pertaining to Time Warner merger with AT&T. Miller says the DOJ will have to address why Delrahim changed his mind on whether the merger meets his antitrust parameters. The analyst keeps his Hold rating on Time Warner and nudges his price target to $103 from $102.
11/13/17
PIVT
11/13/17
UPGRADE
Target $103
PIVT
Buy
Time Warner upgraded to Buy from Hold at Pivotal Research
Pivotal Research analyst Brian Wieser upgraded Time Warner (TWX) to Buy from Neutral and raised its price target to $103 from $102. The analyst is confident that some kind of transaction with AT&T (T) will eventually occur and said shares already have fallen from low levels on reduced confidence. Wieser said Time Warner is worth $81 on a stand-alone basis and views downside as limited.
11/13/17
RSBL
11/13/17
UPGRADE
RSBL
Buy
Time Warner upgraded to Buy from Neutral at Rosenblatt
Rosenblatt analyst Alan Gould upgraded Time Warner (TWX) to Buy from Neutral with a $103 price target, up from $102. The analyst said AT&T's (T) offer is now valued at $103, but may take till April to close, instead of year end, if the Department of Justice sues to block the deal Gould believes shares are now at a level that offers the most compelling risk/reward under coverage, and sees minimal downside even it the deal falls apart, which he does not expect.
GE General Electric
$18.21

-0.04 (-0.22%)

11/14/17
RBCM
11/14/17
DOWNGRADE
Target $20
RBCM
Sector Perform
GE downgraded to Sector Perform at RBC Capital on protracted turnaround
As reported earlier, RBC Capital analyst Deane Dray downgraded General Electric to Sector Perform from Outperform and cut his price target to $20 from $25. Dray says that he now expects the turnaround at the company to be more protracted than previously anticipated, noting the roadmap laid out by new CEO John Flannery fell short of expectations regarding the scope of the business model/portfolio changes. The analyst says the investment community was especially disappointed by the scope of the "missteps and secular challenges", as well as the systemic cash flow shortfalls, in the Power segment, along with the disclosure that the company's dividend payout was above the scope of industrial cash flows for several years.
11/14/17
BOFA
11/14/17
NO CHANGE
Target $23
BOFA
Buy
BofA/Merrill sticking with a Buy on General Electric
BofA/Merrill analyst Andrew Obin said General Electric's dividend cut and lowered 2018 outlook are a "true reset" while the $6B pension refunding in 2018 through debt issuance should reduce some of the concerns about off-balance sheet liabilities. Obin said the company is focused on the core portfolio and is evaluating other options withing its portfolio, where there is significant optionality. The analyst did cut his estimates and reduced his price target on General Electric shares to $23 from $27 but is sticking with his Buy rating.
11/14/17
11/14/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. General Electric (GE) downgraded to Sector Perform from Outperform at RBC Capital with analyst Deane Dray saying that he now expects the turnaround at the company to be more protracted than previously anticipated, noting the roadmap laid out by new CEO John Flannery fell short of expectations regarding the scope of the business model/portfolio changes. 2. Phillips 66 (PSX) downgraded to Underweight from Equal Weight at Barclays analyst Paul Cheng saying the company's diversified business model will likely drive underperformance in a strong margin uptrend environment for U.S. refiners. 3. Hilton (HLT) downgraded to Buy from Conviction Buy at Goldman Sachs with analyst Stephen Grambling citing the recent outperformance of the stock for the rating change, but he expects consistent double-digit earnings growth on low single-digit RevPAR. 4. PulteGroup (PHM) downgraded to Neutral from Buy at Buckingham with the firm citing recent share strength and raised its price target to $33 from $31. 5. Albemarle (ALB) downgraded to Hold from Buy at Deutsche Bank with analyst David Begleiter downgraded Albemarle (ALB) to Hold from Buy while raising his price target for the shares to $150 from $130. Following a field trip to China, Begleiter believes new lithium processing capacity is coming, which should begin to pressure prices by 2019. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/14/17
COWN
11/14/17
NO CHANGE
COWN
Market Perform
Woodward may have negative read through from GE Power guidance, says Cowen
Cowen analyst Guatam Khanna noted that General Electric (GE) has reduced its outlook for its Power segment and said it will seek to pare back delivery of gas turbine part orders that have already been placed. All of this may add pressure to Woodward's (WWD) FY18 industrial segment guidance, said Khanna, who has a Market Perform rating on Woodward shares.
IBM IBM
$148.97

-0.15 (-0.10%)

11/16/17
PIPR
11/16/17
NO CHANGE
Target $60
PIPR
Overweight
NetApp price target raised to $60 from $52 at Piper Jaffray
Piper Jaffray analyst Andrew Nowinski raised his price target for NetApp to $60 saying the company reported "very strong" Q2 results, with all metrics exceeding the mid-point of guidance and consensus. The quarter shows that NetApp continues to take share from HP (HPQ), Dell/EMC and IBM (IBM), Nowinski tells investors in a post-earnings research note. He expects the share gains to continue and reiterates an Overweight rating on NetApp shares.
10/27/17
PIVT
10/27/17
INITIATION
Target $180
PIVT
Buy
IBM initiated with a Buy at Pivotal Research
Pivotal Research analyst Lou Miscioscia initiated IBM (HPE) with a Buy and $180 price target. The analyst prefers IBM to HP Enterprise (HPE) due to its more complete IT approach led by services and with Digital Hardware/software solutions. Miscioscia said IBM's valuation is at the low end of peers and after years of turnaround efforts is finally positioned to grow.
10/18/17
BMOC
10/18/17
NO CHANGE
Target $170
BMOC
Market Perform
IBM price target raised to $170 from $167 at BMO Capital
BMO Capital analyst Keith Bachman raised his price target on IBM to $170 and maintained a Market Perform rating following Q3 earnings. Bachman says IBM had "reasonable results" for the first time in many quarters, and while Global Business Services and Tech Solutions underwhelmed, Cognitive Solutions returned to modest growth.
10/27/17
10/27/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. IBM (IBM) initiated with a Buy at Pivotal Research. 2. Alder Biopharmaceuticals (ALDR) initiated with a Buy at Canaccord. 3. Biogen (BIIB) initiated with a Hold at Canaccord. 4. Okta (OKTA) initiated with a Buy at SunTrust. 5. Carvana (CVNA) initiated with a Market Perform at Barrington. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
BHGE Baker Hughes
$30.91

0.76 (2.52%)

10/19/17
UBSW
10/19/17
INITIATION
Target $36
UBSW
Neutral
Baker Hughes initiated with a Neutral at UBS
UBS analyst Angie Sedita started Baker Hughes with a Neutral rating and $36 price target. The shares are "compelling" for conservative investors looking for less leverage to oil prices and those seeking a "strong" balance sheet and a dividend, Sedita tells investors in a research note. The analyst, however, believes the current valuation of Baker Hughes is fair.
10/19/17
10/19/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Baker Hughes (BHGE) initiated with a Neutral at UBS. 2. Wayfair (W) initiated with a Buy at MKM Partners. 3. TerraForm Power (TERP) reinstated with a Neutral at JPMorgan. 4. Eiger BioPharmaceuticals (EIGR) initiated with a Buy at Roth Capital. 5. Northern Dynasty (NAK) initiated with a Buy at H.C. Wainwright. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/23/17
LOOP
10/23/17
NO CHANGE
Target $37
LOOP
Hold
Baker Hughes price target lowered to $37 from $40 at Loop Capital
Loop Capital analyst Stephen Gengaro lowered his price target on Baker Hughes to $37 following Q3 results, noting the company's near-term prospects are shadowed by headwinds in its Oilfield Equipment segment, soft international Oilfield Service demand, and a tepid short-term environment for LNG-driven work. The analyst notes however that management feels good about its synergy targets in its facility integration process. Gengaro maintains a Hold rating on Baker Hughes.
10/24/17
UBSW
10/24/17
NO CHANGE
UBSW
Selloff in oil services not necessarily over, says UBS
UBS analyst Angie Sedita said the recent sell off in the oil services sector is not necessarily over as short-term investors continue to unwind positions and she believes some Street estimates are still too high. She remains constructive on the group long-term, but attributes the selloff to a lack of upward guidance, limited catalysts, limited visibility on E&P capital expenditures and some downward revisions on some larger names in the group.
HMC Honda
$32.62

0.02 (0.06%)

09/05/17
MSCO
09/05/17
DOWNGRADE
MSCO
Equal Weight
Honda downgraded to Equal Weight from Overweight at Morgan Stanley
08/01/17
NOMU
08/01/17
UPGRADE
NOMU
Neutral
Honda upgraded to Neutral from Reduce at Nomura Instinet
07/05/17
JPMS
07/05/17
DOWNGRADE
JPMS
Honda downgraded to Neutral from Overweight at JPMorgan
11/17/17
MUFG
11/17/17
UPGRADE
MUFG
Neutral
Honda upgraded to Neutral from Underweight at MUFG
GLPG Galapagos NV
$90.83

-0.66 (-0.72%)

09/15/17
STFL
09/15/17
NO CHANGE
Target $120
STFL
Buy
Galapagos NV price target raised to $120 from $101 at Stifel
After hosting a call with two key opinion leaders on idiopathic pulmonary fibrosis, Stifel analyst Adam Walsh noted that the physicians expressed the view that the efficacy of GLPG1690 in the Phase 2 FLORA trial "was as good as one could have hoped for." As a result of the positive physician feedback, he increased his probability of success for '1690 to 15% from 10% and raised his price target on Galapagos to $120 from $101. Walsh keeps a Buy rating on Galapagos shares.
09/14/17
RBCM
09/14/17
INITIATION
Target $98
RBCM
Sector Perform
Galapagos NV initiated with a Sector Perform at RBC Capital
RBC Capital analyst Brian Abrahams started Galapagos NV with a Sector Perform rating and $98 price target.
08/14/17
JEFF
08/14/17
NO CHANGE
JEFF
Buy
Expert IPF call positive for FibroGen, says Jefferies
Jefferies analyst Michael Yee says his call with two idiopathic pulmonary fibrosis experts was net positive for FibroGen (FGEN). Based on the available data, the experts estimated a 30%-40%-plus probability of success in Phase 3 for the company. The experts were "more conservative in the interpretation" of the data reported by Galapagos NV (GLPG), Yee tells investors in a research note. He reiterates a Buy rating on FibroGen given the "underappreciated value" for FG-3019 in IPF.
08/11/17
STFL
08/11/17
UPGRADE
Target $101
STFL
Buy
Stifel upgrades Galapagos with $101 target on 'clearly positive' data
Stifel analyst Adam Walsh upgraded Galapagos NV to Buy from Hold and raised his price target for the shares to $101 from $83. The stock closed yesterday up 11%, or $7.89, to $81.06. The early Phase 2 results for wholly-owned GLPG1690 in idiopathic pulmonary fibrosis were "clearly positive," Walsh tells investors in a research note. The analyst included the drug in his model with a "very reasonable" 10% probability of success. Further, he sees "reduced downside risk" associated with Galapagos' cystic fibrosis triple combo.

TODAY'S FREE FLY STORIES

DHI

D.R. Horton

$43.36

0.34 (0.79%)

13:00
04/23/18
04/23
13:00
04/23/18
13:00
Options
DR Horton draws far upside call writing ahead of earnings »

DR Horton draws far…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

FB

Facebook

$167.80

1.51 (0.91%)

12:58
04/23/18
04/23
12:58
04/23/18
12:58
Hot Stocks
DoubleLine's Gundlach says go short Facebook »

Jeffrey Gundlach, CEO,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 25

    Apr

XOP

SPDR Oil Exploration and Production Fund

$38.82

-0.06 (-0.15%)

12:58
04/23/18
04/23
12:58
04/23/18
12:58
Hot Stocks
DoubleLine's Gundlach says go long SPDR Oil Exploration and Production Fund »

Jeffrey Gundlach, CEO,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APDN

Applied DNA Sciences

12:56
04/23/18
04/23
12:56
04/23/18
12:56
Initiation
Applied DNA Sciences initiated  »

Applied DNA Sciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

FB

Facebook

$167.77

1.48 (0.89%)

12:55
04/23/18
04/23
12:55
04/23/18
12:55
Hot Stocks
DoubleLine's Gundlach calls apology by Facebook's Zuckerberg 'disingenuous' »

Jeffrey Gundlach, CEO,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 25

    Apr

WPG

Washington Prime

12:50
04/23/18
04/23
12:50
04/23/18
12:50
Options
Washington Prime with notable put buying ahead of earnings »

Washington Prime with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

AAPL

Apple

$165.70

-0.01 (-0.01%)

12:48
04/23/18
04/23
12:48
04/23/18
12:48
Hot Stocks
CIRP: iPhone X demand slows as iPhone 8, 8 Plus mix climbs in March quarter »

Consumer Intelligence…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

OAS

Oasis Petroleum

$10.16

0.01 (0.10%)

12:45
04/23/18
04/23
12:45
04/23/18
12:45
Options
Oasis Petroleum call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

ASND

Ascendis Pharma

$63.01

-0.82 (-1.28%)

12:45
04/23/18
04/23
12:45
04/23/18
12:45
Conference/Events
Ascendis Pharma has a conference call hosted by JPMorgan »

JPMorgan Analyst Fye will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 08

    May

  • 10

    May

CNSL

Consolidated Communications

$10.94

-0.04 (-0.36%)

12:41
04/23/18
04/23
12:41
04/23/18
12:41
Hot Stocks
Consolidated Communications launches DDoS mitigation solution »

Consolidated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INCY

Incyte

$68.72

0.31 (0.45%)

, LLY

Eli Lilly

$79.47

0.38 (0.48%)

12:36
04/23/18
04/23
12:36
04/23/18
12:36
Recommendations
Incyte, Eli Lilly analyst commentary  »

Incyte AdCom meeting…

INCY

Incyte

$68.72

0.31 (0.45%)

LLY

Eli Lilly

$79.47

0.38 (0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 23

    Apr

  • 24

    Apr

  • 01

    May

  • 07

    May

  • 21

    May

  • 07

    Jun

  • 07

    Jun

  • 12

    Jun

GRUB

GrubHub

$103.01

1.32 (1.30%)

12:35
04/23/18
04/23
12:35
04/23/18
12:35
Hot Stocks
Half Sky's Ran says GrubHub has 'significant room for growth' »

Says young people are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 29

    May

  • 12

    Jun

GRUB

GrubHub

$103.59

1.9 (1.87%)

12:30
04/23/18
04/23
12:30
04/23/18
12:30
Hot Stocks
Half Sky's Ran says GrubHub is "attractive investment idea" »

Li Ran, CIO, Half Sky…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 29

    May

  • 12

    Jun

LITE

Lumentum

$57.25

-1.65 (-2.80%)

12:27
04/23/18
04/23
12:27
04/23/18
12:27
Hot Stocks
Lumentum falls to session lows, down 5% »

Shares of Lumentum have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 29

    May

DHI

D.R. Horton

$43.22

0.2 (0.46%)

12:26
04/23/18
04/23
12:26
04/23/18
12:26
Hot Stocks
Long Pond's Khoury sees D.R. Horton at $71.50 per share »

Says incredibly strong…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

12:25
04/23/18
04/23
12:25
04/23/18
12:25
General news
NABE Business Conditions Survey showed strong sales expectations »

NABE Business Conditions…

12:25
04/23/18
04/23
12:25
04/23/18
12:25
Conference/Events
Leerink healthcare analysts to hold an analyst/industry conference call »

Analysts discuss dental…

PRTA

Prothena

$11.54

-25.35 (-68.72%)

, RHHBY

Roche

12:23
04/23/18
04/23
12:23
04/23/18
12:23
Recommendations
Prothena, Roche analyst commentary  »

Prothena price target…

PRTA

Prothena

$11.54

-25.35 (-68.72%)

RHHBY

Roche

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 27

    Apr

  • 27

    Apr

  • 21

    May

  • 30

    May

VZ

Verizon

$48.36

0.44 (0.92%)

, T

AT&T

$34.76

0.09 (0.26%)

12:22
04/23/18
04/23
12:22
04/23/18
12:22
Earnings
On The Fly: What to watch in telecom sector earnings reports »

Verizon (VZ) is scheduled…

VZ

Verizon

$48.36

0.44 (0.92%)

T

AT&T

$34.76

0.09 (0.26%)

S

Sprint

$5.91

-0.085 (-1.42%)

TMUS

T-Mobile

$62.59

-0.51 (-0.81%)

TWX

Time Warner

$96.13

-0.1 (-0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 24

    Apr

  • 24

    Apr

  • 25

    Apr

  • 09

    May

AMZN

Amazon.com

$1,535.44

8.05 (0.53%)

, MGM

MGM Resorts

$36.31

0.88 (2.48%)

12:21
04/23/18
04/23
12:21
04/23/18
12:21
Periodicals
'Fortnite' stream in Las Vegas peaked at 667,000 viewers on Twitch, ESPN says »

A high-profile…

AMZN

Amazon.com

$1,535.44

8.05 (0.53%)

MGM

MGM Resorts

$36.31

0.88 (2.48%)

TCEHY

Tencent

DIS

Disney

$100.22

-0.02 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 26

    Apr

  • 08

    May

NCR

NCR Corp.

$31.52

-0.03 (-0.10%)

12:20
04/23/18
04/23
12:20
04/23/18
12:20
Options
New positions opened in NCR calls ahead of earnings »

New positions opened in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHI

D.R. Horton

$43.11

0.09 (0.21%)

12:19
04/23/18
04/23
12:19
04/23/18
12:19
Hot Stocks
Long Pond's Khoury says D.R. Horton is transforming into pure play manufacturer »

Says transformation from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

MMM

3M

$217.06

-0.66 (-0.30%)

12:18
04/23/18
04/23
12:18
04/23/18
12:18
Technical Analysis
Technical Take: 3M in downtrend ahead of earnings news »

The stock has been in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

  • 18

    May

  • 30

    May

$NSD

NASDAQ Market Internals

12:17
04/23/18
04/23
12:17
04/23/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

12:16
04/23/18
04/23
12:16
04/23/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.